|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1997-7-21
|
|
pubmed:abstractText |
To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2378-84
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9196153-Adolescent,
pubmed-meshheading:9196153-Adult,
pubmed-meshheading:9196153-Aged,
pubmed-meshheading:9196153-Antineoplastic Agents, Alkylating,
pubmed-meshheading:9196153-Bone Neoplasms,
pubmed-meshheading:9196153-Dose-Response Relationship, Drug,
pubmed-meshheading:9196153-Drug Administration Schedule,
pubmed-meshheading:9196153-Drug Therapy, Combination,
pubmed-meshheading:9196153-Female,
pubmed-meshheading:9196153-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:9196153-Humans,
pubmed-meshheading:9196153-Ifosfamide,
pubmed-meshheading:9196153-Male,
pubmed-meshheading:9196153-Mesna,
pubmed-meshheading:9196153-Middle Aged,
pubmed-meshheading:9196153-Pilot Projects,
pubmed-meshheading:9196153-Sarcoma,
pubmed-meshheading:9196153-Soft Tissue Neoplasms,
pubmed-meshheading:9196153-Treatment Outcome
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
|
|
pubmed:affiliation |
The Sarcoma Center, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. shreyaskumar_patel@mel_sarc.mda.uth.tmc.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
